Anixa Biosciences (ANIX) Income from Continuing Operations (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Income from Continuing Operations came in at 4003000.0 in Q2 2026, down 14.21% YoY from 4665951.11 in Q2 2025, and up 99.95% on a QoQ basis from 7376874000.0 in Q4 2025.
Anixa Biosciences (ANIX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Income from Continuing Operations data on file, last reported at 4003000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 14.21% year-over-year to 4003000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 7388369000.0 (down 13760.56% YoY) and the FY2025 annual result came in at 7385180000.0, down 263.99% from the prior year.
- Income from Continuing Operations rose to 4003000.0 in Q2 2026, from 7376874000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3505000.0 in Q2 2025 to a low of 34504721000.0 in Q4 2023.
- A 5-year average of 4211834352.94 and a median of 4959000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 726001.77% — and 2024, when it soared 99.88%.
- Tracing ANIX's Income from Continuing Operations over 5 years: stood at 29605529000.0 in 2022, then dropped by 16.55% to 34504721000.0 in 2023, then soared by 99.88% to 40666000.0 in 2024, then tumbled by 18040.15% to 7376874000.0 in 2025, then soared by 99.95% to 4003000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4003000.0 (Q2 2026), 7376874000.0 (Q4 2025), and 3987000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | -2.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -4.00 Mn |
| Oct 31, 2025 | -7.38 Bn |
| Jul 31, 2025 | -3.99 Mn |
| Apr 30, 2025 | -3.51 Mn |
| Jan 31, 2025 | -4.31 Mn |
| Oct 31, 2024 | -40.67 Mn |
| Jul 31, 2024 | -4.83 Mn |
| Apr 30, 2024 | -3.76 Mn |
| Jan 31, 2024 | -12.53 Mn |
| Oct 31, 2023 | -34.50 Bn |
| Jul 31, 2023 | -4.86 Mn |
| Apr 30, 2023 | -6.99 Mn |
| Jan 31, 2023 | -9.27 Mn |
| Oct 31, 2022 | -29.61 Bn |
| Jul 31, 2022 | -5.85 Mn |
| Apr 30, 2022 | -4.96 Mn |
| Jan 31, 2022 | -4.56 Mn |
| Oct 31, 2021 | -4.08 Mn |
| Jul 31, 2021 | -9.55 Mn |
| Apr 30, 2021 | -9.44 Mn |